Replies to post #444141 on Anavex Life Sciences Corp (AVXL)

[williamssc]

Does sound put on. Just a three years ago this stock ran to $30. I think the shorts are boxed in.

[rayovac812]

How can anyone be disappointed by this outcome? Wow

I think blaming the CEO is misappropriation. Anyone in any position knows how often companies change their focus. The reason is that new management and executives come into the picture and put their stamp on a new direction, to justify their hiring. As we have seen when they get replaced when a drug fails, it doesn't always end up as justification.

It has already been said. Moving goal posts are inherent in biotech, and all companies beyond biotech do it as well. Why wouldn't directional or focus changes come with the hiring of an FDA asset? Beyond their professional abilities, there is an added benefit of demonstrating that Anavex hires FDA people. That tends to be a small selling point when it is time for your drug to be analyzed. The data itself is by far the larger selling point. Absent an ability to offer a better Rett or AD alternative, that places Blarcamesine as best in class on every level conceivable, and virtually assures approval.

There too, is no way anyone should view time estimates as self imposed deadlines, especially in biotech. I want aggressive goals and I expect that time estimates will be off. It isn't as easy as making a doctors appointment, or scheduling a delivery date. If there is an expectation that everything is or should be on time, then the question of what color is the sky on your planet....is appropriate. If/when time estimates hit the bullseye, great...but if you think predicting the future is easy, make predictions.